The Supreme Court Did Protect Telehealth Abortion Pill Access — But Not Because of a Safety Review

The claim is partially true but importantly misleading. Yes, the Supreme Court took action that kept FDA telehealth mifepristone prescriptions in place. But the reason has nothing to do with a safety review — and that distinction matters a lot.

Here is what actually happened. In April 2023, the Supreme Court issued a procedural stay blocking a lower court ruling that would have restricted mifepristone access. That was a temporary hold during litigation, not a judgment tied to any safety assessment. Then in June 2024, the Court issued its final ruling in FDA v. Alliance for Hippocratic Medicine — unanimously, 9-0 — and telehealth access was preserved again.

But the reason the Court ruled that way was purely technical. According to the Supreme Court's own opinion and reporting from NPR and Reuters, the anti-abortion doctors and groups who brought the lawsuit simply did not have legal standing — meaning they had no recognized legal right to sue in the first place. The Court never evaluated whether mifepristone is safe. It never ordered or referenced a safety review. The case was thrown out on a procedural door, not decided on the merits.

As for the FDA, it has not launched a new formal safety review of mifepristone. The agency approved the drug in 2000 and, per its own published information, considers its safety profile well-established after more than two decades of use. There is no open review process that the Supreme Court was managing or waiting on.

This kind of half-true claim is worth watching for. It takes real events — a genuine Supreme Court action, real telehealth access — and wraps them in a framing that implies the drug's safety is an open question under active government scrutiny. That implication is false, but it sounds plausible because the underlying facts are real.